Studies of epigenetic alterations in cancer, such as aberrant methylation and altered transcription factor binding, can provide insight into important tumorigenic pathways. As altered methylation often activates or silences genes, changes in the epigenome can affect gene expression and the rate of cancer progression.
Next-generation sequencing (NGS) and microarray technologies can detect altered methylation patterns and other epigenetic changes in cancer.
Methylation arrays enable epigenome-wide association studies that analyze multiple samples in parallel. Arrays quantitatively interrogate methylation sites across the genome, providing insight into the regulation of cancer genes and pathways.Learn More About Methylation Arrays
Altered transcription factor binding is a common epigenetic pattern in cancer. Chromatin immunoprecipitation sequencing (ChIP-Seq) experiments provide a complete snapshot of DNA regions associated with a protein of interest.Learn More About ChIP-Seq
Researchers use the Illumina Methylation array on tumor and PBLs to identify differences in breast tumor development between African American and non-African American women.Learn More
A methylation fingerprint is used to stratify medulloblastoma subgroups for improved characterization.Learn More
A review of recent epigenetic discoveries in prostate cancer, highlighting their potential as biomarkers for diagnosis, segmentation, and monitoring.Learn More